FDA has removed CAR-T access barriers to boost cancer immunotherapy uptake. (27/06/25)
FDA has removed 'risk evaluation and mitigation strategies (REMS) for currently approved BCMA and CD-19 therapies.
Potentially significant news for Azer-cel and Oncarlytic platforms.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.2¢ |
Change
-0.001(7.69%) |
Mkt cap ! $89.60M | |||
| Open | High | Low | Value | Volume |
| 1.3¢ | 1.3¢ | 1.2¢ | $140.7K | 11.14M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 48 | 12072742 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 11000727 | 22 |
View Market Depth
| Last trade - 14.43pm 30/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |